الگوی پیش بین های عملکرد استراتژی تجاری سازی مستقل در صنعت داروهای زیستی ایران (مقاله علمی وزارت علوم)
درجه علمی: نشریه علمی (وزارت علوم)
آرشیو
چکیده
زیست فناوری پزشکی یا درمانی به توسعه ابزارهای تحقیقاتی، تشخیص، توسعه و تحویل داروها و واکسن ها از طریق استفاده از سیستم ها یا فرآیندهای سلولی و مولکول های زیستی اختصاص دارد. یک انتخاب استراتژیک بسیار مهم شرکت ها در صنعت داروهای زیستی، استراتژی تجاری سازی فناوری است. استراتژی تجاری سازی مستقل به عنوان یکی از استراتژی های تجاری سازی داروهای زیستی در دنیا شناخته شده است. هدف پژوهش حاضر شناسایی پیش بین های عملکرد استراتژی تجاری سازی مستقل در صنعت زیست داروی ایران با استفاده از روش فراترکیب است. در این روش پس از فیلتر مقالات، در نهایت تعداد 42 تحقیق که بطور مستقیم به موضوع عملکرد تجاری سازی مستقل در داروهای زیستی پرداخته بودند وارد مرحله تحلیل در نرم افزار مکس کیودا شدند. پس از مرحله تلفیق تعداد 68 رمز متمایز شناسایی، و در سطوح انتزاع بالاتر رمزها در قالب 9 تم (جهت گیری استراتژیک، هوش تجاری سازی فناوری، قابلیت R&D، یکپارچگی دانش توسعه محصول، قابلیت تجاری سازی (تولید و بازاریابی)، مکانیسم حمایتی دولت و رژیم های مالکیت، یکپارچگی رسمی و پویائی محیطی) قرار داده شدند. به منظور ساخت مدل مفهومی پژوهش، براساس خروجی فراترکیب، سازه های پیش بین عملکرد استراتژی تجاری سازی مستقل، نحوه ارتباط سازه ها و نیز شاخص های اندازه گیری آنها استخراج شدند. نتیجه اعتبارسنجی مدل پیشنهادی براساس نظر خبرگان صنعت زیست داروئی کشور با روش رتبه اعتبار محتوایی لاوش و تکنیک حداقل مربعات جزئی از این قرار است: پیش بین های عملکرد استراتژی تجاری سازی مستقل با ضریب تعیین 91% عبارتند از: یکپارچگی رسمی و غیررسمی، جهت گیری های استراتژیک، هوش تجاری سازی فناوری، قابلیتR&D، قابلیت تولید و بازاریابی.The Model of Performance Predictors of Independent Commercialization Strategy in the Iranian Bio-Pharmaceutical Industry
Medical or therapeutic biology is dedicated to the development of research tools, diagnosis, development and delivery of drugs and vaccines through the use of cellular systems or processes and biological molecules. A very important strategic choice of companies in the biological drug industry is technology trading strategy. Independent commercialization strategy is recognized as one of the trade drugs in the world. The purpose of the present study is to identify predictions for the performance of independent commercialization strategy in Iran's biological industry using a comprehensive method. In this method, after the filtering of the articles, finally 42 studies that directly addressed the performance of independent commercialization in biological drugs entered the analysis phase of the Maxicioda software. After the combination of 68 distinct passwords, and at higher ion levels of the passwords in the form of 9 themes (strategic orientation, technology commercialization intelligence, R&D capability, product development knowledge integration, commercialization (production and marketing), The state -supporting mechanism of government and ownership regimes, formal integration and environmental dynamics were set. In order to construct the conceptual model of the research, they were extracted based on the component output, predictive structures of independent trading strategy, how the structures communication, and their measurement indicators were extracted. The validity of the proposed model based on the country's biotechnology experts with the Lavos content validity method and the minimum square minimum technique is: Independent commercial strategy performance predictions with a 91% determination coefficient include: Official integrity and integrity. Innovation, strategic orientation, technology commercialization, R&D capability, production capability and marketing. Introduction Biotechnology is an important part of the society and economy of Iran. In the world, 140 drugs are produced from biotechnology, of which 16 are the most commonly used drugs. Nowadays 9 biotechnology and vaccine drugs such as hepatitis B drugs and various types of interferons (alpha, gamma and beta) are produced inside the country, producing 250 billion tomans worth of currency savings for the country. About $ 8 billion worth of biotechnology imports into the country are expected to cost $ 150 billion annually, which is expected to increase by about 900-800 billion USD annually. Biotechnology drugs are expensive drugs and if we can plan to produce these drugs in the next five years, we have to pay a thousand billion dollars for the import of such drugs, which will disrupt the health and medicine system of the country. This implicitly implies the necessity of commercialization, the formulation of commercialization strategies, and the successful performance of commercialization strategies in the field of biotechnology (Kebriaeezadeh et al., 2010). The question that is posed is that the predictors (determinants) of the operation of the independent commercialization strategy in Iran's bio-environmental industry? Case Study In the present research, the industry of biological drugs in Iran has been studied. Materials and Method The present study is based on the results of development; on the basis of purpose, explanatory-descriptive and based on the type of data is quantitative and the research quality is a hypothesis test. The design of the research has been done according to the five-step approach presented by McKinsey et al. (1999). Accordingly, the research stages are as follows: the design of the research includes the explanation of the problem and the review of the theoretical background; the formulation of a conceptual framework and the determination of the components and relevant indicators; validation of the research including general validation, validation of the research tool and data collection; analysis and Data analysis; Reporting the results of the research including summarizing the findings of research and writing the analyzes of the researchers. Results and Discussion Considering the content validity ratios calculated, in the conceptual model, the predictors of the performance of the independent commercialization strategy, the factors; the strategic orientation, the formal and informal integration of research units with the units of production and marketing, the ability to R & D, commercialization and intelligence of technology commercialization are the determinants of the operation of an independent commercialization strategy in the country's biotechnology industry.According to the model of performance prediction of independent commercialization strategy in the country's biotechnology industry, the following hypotheses have been developed. Hypothesis 1. There is a significant relationship between BI-technology intelligence and the performance of the development of a new biological medicine. Hypothesis 2. There is a significant relationship between the integrity (formal and informal) and the performance of the development of the new biological drug. Hypothesis 3. There is a significant relationship between firm strategic orientation and technology commercialization intelligence. Hypothesis 4. There is a significant relationship between the R & D capability and the performance of the new biological drug development. Hypothesis 5. There is a significant relationship between the commercialization (production and marketing) of the firm and the performance of the development of the new biological drug. Hypothesis 6. There is a significant relationship between R & D capability and commercialization (production and marketing) capabilities of the firm. Conclusion Considering the significant relationships between the structure of the company's research and development capability, the structure of the enterprise's commercialization (production and marketing), the strategic directional structure of the firm, the formal and informal integration structure, the technology intelligence technology intelligence structure with the performance of the new product development, It can be said that in the case of: the existence of a suitable R & D workforce, proportional investment in R & D, and ..., we can expect a successful performance (the realization of new product objectives; new product life cycle management; the success of engaging in business activities; Making technology in comparison with direct rivals of the company; a significant increase in corporate revenues versus commercialization revenues Direct use; the company's more successful use of technology commercialization for strategic purposes in comparison with its competitors; providing unique features to customers; increasing the number of patents obtained from the new product development program; receiving good returns to costs; The program used for the new product development program and the competitiveness of the new product in the market) had an independent commercialization strategy.
تبلیغات
